Show simple item record

dc.contributor.authorCunningham, D
dc.contributor.authorStenning, S
dc.contributor.authorSmyth, E
dc.contributor.authorOkines, A
dc.contributor.authorAllum, W
dc.contributor.authorRowley, S
dc.contributor.authorStevenson, L
dc.contributor.authorGrabsch, H
dc.contributor.authorAlderson, D
dc.contributor.authorCrosby, T
dc.contributor.authorGriffin, S
dc.contributor.authorMansoor, Was
dc.contributor.authorCoxon, F
dc.contributor.authorFalk, S
dc.contributor.authorDarby, S
dc.contributor.authorSumpter, K
dc.contributor.authorBlazeby, J
dc.contributor.authorLangley, R
dc.date.accessioned2017-02-24T09:42:07Z
dc.date.available2017-02-24T09:42:07Z
dc.date.issued2017-02-02
dc.identifier.citationPeri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. 2017, Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid28163000
dc.identifier.doi10.1016/S1470-2045(17)30043-8
dc.identifier.urihttp://hdl.handle.net/10541/620160
dc.description.abstractPeri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safety and efficacy of adding bevacizumab to peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titlePeri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Royal Marsden NHS Foundation Trust, London, UKen
dc.identifier.journalThe Lancet Oncologyen
refterms.dateFOA2018-12-17T14:48:15Z
html.description.abstractPeri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding to treatment in advanced gastric cancer. We aimed to assess the safety and efficacy of adding bevacizumab to peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma.


Files in this item

Thumbnail
Name:
lanc onco.pdf
Size:
635.3Kb
Format:
PDF
Description:
Full text, Open Access Article

This item appears in the following Collection(s)

Show simple item record